Edition:
India

Insmed Inc (INSM.OQ)

INSM.OQ on NASDAQ Stock Exchange Global Select Market

30.33USD
17 Nov 2017
Change (% chg)

$-0.60 (-1.94%)
Prev Close
$30.93
Open
$30.75
Day's High
$30.92
Day's Low
$29.95
Volume
178,427
Avg. Vol
343,235
52-wk High
$32.84
52-wk Low
$11.49

Latest Key Developments (Source: Significant Developments)

Insmed Q3 loss per share $0.69
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Insmed Inc :Insmed reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.69.Q3 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.  Full Article

Insmed says offering of 12.3 million common shares priced at $28.50per share
Thursday, 7 Sep 2017 

Sept 6 (Reuters) - Insmed Inc -:Insmed announces pricing of public offering of common stock.Says offering of 12.3 million common shares priced at $28.50per share.  Full Article

Insmed announces worldwide license agreement with AstraZeneca for oral DPP1 inhibitor
Wednesday, 5 Oct 2016 

Insmed Inc : Insmed will pay AstraZeneca an upfront payment of $30 million . Agreement provides AstraZeneca with option to negotiate a future agreement with Insmed for commercialization of AZD7986/ins1007 . Continue to expect patient enrollment in phase 3 study of Arikayce to conclude later this year and to report top line data in 2017 . Confirms its cash operating expense guidance for second half of 2016 of $62 million to $72 million . In a phase 1 study of healthy volunteers AZD7986 was well tolerated . Says AstraZeneca will be eligible to receive future payments totaling $120 mln in future clinical, regulatory, and sales-related milestones .Confirms its cash operating expense guidance for second half of 2016 of $62 to $72 million..  Full Article

Insmed Q2 loss per share $0.59
Thursday, 4 Aug 2016 

Insmed Inc : Q2 loss per share $0.59 . Insmed reports second quarter 2016 financial results .Q2 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S.  Full Article

Insmed says withdraws marketing application for Arikayce in Europe
Thursday, 9 Jun 2016 

Insmed Inc : Insmed Inc - announces withdrawal of marketing authorization application for arikayce in europe . Insmed Inc says marketing application filing was based on data from co's completed phase 2 study . Insmed Inc - During may 2016 chmp meeting, the panel indicated that phase 2 study did not provide a sufficient amount of evidence to support an approval .Insmed inc says it intends to resubmit its application for arikayce when clinical data from its ongoing global phase 3 study are available..  Full Article

BRIEF-Insmed Q3 loss per share $0.69

* Insmed reports third quarter 2017 financial results and provides business update